A Balanced Look at the Implications of Genomic (and Other “Omics”) Testing for Disease Diagnosis and Clinical Care

The tremendous increase in DNA sequencing capacity arising from the commercialization of “next generation” instruments has opened the door to innumerable routes of investigation in basic and translational medical science. It enables very large data sets to be gathered, whose interpretation and conversion into useful knowledge is only beginning. A challenge for modern healthcare systems and academic medical centers is to apply these new methods for the diagnosis of disease and the management of patient care without unnecessary delay, but also with appropriate evaluation of the quality of data and interpretation, as well as the clinical value of the insights gained. Most critically, the standards applied for evaluating these new laboratory data and ensuring that the results and their significance are clearly communicated to patients and their caregivers should be at least as rigorous as those applied to other kinds of medical tests. Here, we present an overview of conceptual and practical issues to be considered in planning for the integration of genomic methods or, in principle, any other type of “omics” testing into clinical care.

[1]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[2]  David P Bick,et al.  Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease , 2011, Genetics in Medicine.

[3]  Elaine R. Mardis,et al.  A decade’s perspective on DNA sequencing technology , 2011, Nature.

[4]  Euan A Ashley,et al.  Clinical interpretation and implications of whole-genome sequencing. , 2014, JAMA.

[5]  M. Gulley,et al.  Recommended principles and practices for validating clinical molecular pathology tests. , 2009, Archives of pathology & laboratory medicine.

[6]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[7]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[8]  Geert Vandeweyer,et al.  Detection and interpretation of genomic structural variation in health and disease , 2013, Expert review of molecular diagnostics.

[9]  G. Walter,et al.  The Directors , 2006 .

[10]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[11]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[12]  Association of a , 1955 .

[13]  C. Sheridan Illumina claims $1,000 genome win , 2014, Nature Biotechnology.

[14]  J. Forbi,et al.  Molecular epidemiology of viral diseases in the era of next generation sequencing. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  P. Stankiewicz,et al.  Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. , 2010, The New England journal of medicine.

[16]  Heidi L Rehm,et al.  American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss , 2014, Genetics in Medicine.

[17]  G. Abecasis,et al.  Exome sequencing and complex disease: practical aspects of rare variant association studies , 2012, Human molecular genetics.

[18]  Kang Zhang,et al.  DNA sequencing versus standard prenatal aneuploidy screening. , 2014, The New England journal of medicine.

[19]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[20]  Scott D Boyd,et al.  Diagnostic applications of high-throughput DNA sequencing. , 2013, Annual review of pathology.

[21]  J. Ioannidis,et al.  The False-positive to False-negative Ratio in Epidemiologic Studies , 2011, Epidemiology.

[22]  Nancy R Cook,et al.  Association between a literature-based genetic risk score and cardiovascular events in women. , 2010, JAMA.

[23]  E. Lyon,et al.  Revisiting oversight and regulation of molecular-based laboratory-developed tests: a position statement of the Association for Molecular Pathology. , 2014, The Journal of molecular diagnostics : JMD.

[24]  Christine Miller,et al.  Genetic counselor review of genetic test orders in a reference laboratory reduces unnecessary testing , 2014, American journal of medical genetics. Part A.

[25]  R. Klein AMP v Myriad: the Supreme Court gives a win to personalized medicine. , 2013, The Journal of molecular diagnostics : JMD.

[26]  R. Olsen,et al.  Progress and potential: training in genomic pathology. , 2014, Archives of pathology & laboratory medicine.

[27]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[28]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[29]  C. Tifft,et al.  The NIH Undiagnosed Diseases Program: lessons learned. , 2011, JAMA.

[30]  John P. A. Ioannidis,et al.  Research: increasing value, reducing waste 2 , 2014 .

[31]  R. Heim,et al.  Cystic fibrosis carrier testing in an ethnically diverse US population. , 2011, Clinical chemistry.

[32]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[33]  Y. Natkunam,et al.  Integration of genomic medicine into pathology residency training: the stanford open curriculum. , 2013, The Journal of molecular diagnostics : JMD.

[34]  石川 大輔 ミリアッド最高裁判決とUSPTOの新ガイダンス 今後の特許戦略に与える影響は大きい[Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12-398 (2013)] (特集 アメリカで吹き荒れるアンチパテントの嵐) , 2014 .

[35]  Tina Hambuch,et al.  Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. , 2012, The Journal of molecular diagnostics : JMD.

[36]  A. StAteMent Points to consider for informed consent for genome/exome sequencing , 2013, Genetics in Medicine.

[37]  Iris Schrijver,et al.  Test verification and validation for molecular diagnostic assays. , 2012, Archives of pathology & laboratory medicine.

[38]  S. Fullerton,et al.  Return of incidental findings in genomic medicine: measuring what patients value—development of an instrument to measure preferences for information from next-generation testing (IMPRINT) , 2013, Genetics in Medicine.

[39]  J. Ioannidis Why Most Published Research Findings Are False , 2005, PLoS medicine.

[40]  A Cecile J W Janssens,et al.  Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies—A targeted evidence-based review , 2010, Genetics in Medicine.

[41]  J. Zook,et al.  Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls , 2013, Nature Biotechnology.

[42]  M. Boguski,et al.  A call to action: training pathology residents in genomics and personalized medicine. , 2010, American journal of clinical pathology.

[43]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[44]  Shashikant Kulkarni,et al.  Assuring the quality of next-generation sequencing in clinical laboratory practice , 2012, Nature Biotechnology.